PARP Inhibitors in Gastric Cancer: Unlocking Precision Oncology. Read more about PARP Inhibitors in Gastric Cancer: Unlocking Precision Oncology.
Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management. Read more about Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management.
Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure? Read more about Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma. Read more about Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. Read more about Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.
A scoping review of clinical communication in cancer care in Africa. Read more about A scoping review of clinical communication in cancer care in Africa.
Metastatic insulinoma-outcomes in the current era. Read more about Metastatic insulinoma-outcomes in the current era.
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Read more about Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.
Proceedings of the 1st biannual bridging the gaps in lung cancer conference. Read more about Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Immune-related encephalitis after immune checkpoint inhibitor therapy. Read more about Immune-related encephalitis after immune checkpoint inhibitor therapy.
